<DOC>
	<DOC>NCT02920242</DOC>
	<brief_summary>This study will compare safety and efficacy of a generic rifaximin tablet to the reference listed drug in the treatment of travelers' diarrhea. Additionally both the generic and reference formulations will be tested for superiority against a placebo tablet.</brief_summary>
	<brief_title>A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Patient is able to read and understood the language of the Informed Consent Form and Patient Information. International travelers with a duration of stay in host country long enough to attend schedules visits. Affected by naturally acquired acute diarrhea, defined as the passage of at least 3 unformed stools within 24 hours immediately preceding randomization preceding randomization Hypersensitivity to rifaximin or any of the rifamycin antimicrobial agents or to any of the excipients of the study drug. Pregnant, breast feeding or planning pregnancy Acute diarrhea for &gt; 72 hours immediately prior to randomization. Presence of fever (≥ 100 °F/37.8°C) or hematochezia (blood in stool, noted visually) or clinical findings suggesting moderate or severe dehydration. Other protocol inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Travelers</keyword>
	<keyword>diarrhea</keyword>
	<keyword>rifaximin</keyword>
	<keyword>equivalence</keyword>
</DOC>